The acquisition will add Tissuemed’s surgical sealant to BD's suite of biosurgery products already relied upon in the operating room
BD will add advanced sealant to its portfolio of surgical solutions. (Credit: Becton, Dickinson and Company.)
US-based medical device maker BD has acquired Tissuemed, a self-adhesive surgical sealant films provider, for an undisclosed amount.
Tissuemed offers Tissuepatch, a sealant technology that binds to tissues to help control the internal bleeding or prevent leaks from surgical incisions.
With a thin, flexible and transparent composition, the technology is ready to use and is suited for a range of surgical sealant applications.
The acquisition enables BD to add Tissuemed’s surgical sealant to its suite of biosurgery products, being used in the operating room.
The transaction is expected to complement BD’s core portfolio, and help expand its offerings for surgeons outside of the US.
BD Surgery president Kevin Kelly said: “This advanced sealant serves as a strategic complement to the BD products used in the operating room today, providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions.
“Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”
According to BD, Tissuepatch features a design that enables strong adhesive and minimal swelling.
The company will leverage its clinical expertise to advance the sealant technology category, with significant growth plans for the coming five to 10 years.
Earlier this month, BD has acquired Venclose, a provider of next-generation solutions for the treatment of chronic venous insufficiency (CVI), for an undisclosed sum.
Venclose has developed a radio frequency (RF) ablation technology platform for the treatment of CVI, caused due to malfunctioning valves and may lead to varicose veins.
With the acquisition, BD is expected to enter into the CVI treatment area, and adds advanced solutions to its existing venous disease portfolio.